Status:
COMPLETED
Use of Insulin Glargine to Treat Diabetic Ketoacidosis
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
Diabetic Ketoacidosis
Eligibility:
All Genders
6-18 years
Phase:
NA
Brief Summary
The purpose of this study is to determine the effects of the addition of insulin glargine during the early phase of moderate to severe Diabetic Ketoacidosis (DKA) in children. The investigators hypot...
Eligibility Criteria
Inclusion
- Ages 6-18 y.o. presenting to Vanderbilt Children's Hospital (VCH) Emergency Room with:
- Established history of insulin dependent diabetes
- AND:
- Chief c/o hyperglycemia or vomiting
- Venous pH \< 7.24
- Serum Bicarbonate \< 18
- Blood glucose \> 150
- Urinary Ketones
Exclusion
- Age \< 6y.o.
- New onset diabetes
- Received IV insulin bolus prior to arrival to VCH Emergency Room (ER)
- Venous pH \> 7.24
- Serum Bicarbonate \> 18
- Pregnancy
- Received glargine within 12 hours prior to arrival to VCH Emergency Room/Pediatric Critical Care Unit
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00179127
Start Date
August 1 2004
End Date
September 1 2012
Last Update
July 16 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Monroe Carell Children's Hospital
Nashville, Tennessee, United States, 37232